Aandrogen receptor status predicts development of brain metastases in ovarian cancers

Gloria Mittica, Rebecca Senetta, Giulia Scotto, Massimo Aglietta, Furio Maggiorotto, Eleonora Ghisoni, Sofia Genta, Renzo Boldorini, Claudia Manini, Isabella Morra, Roberta Buosi, Anna Sapino, Paola Cassoni, Giorgio Valabrega

Research output: Contribution to journalArticle

Abstract

Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a "Control dataset" of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry forCases (both primary and metastatic lesions) and Controls. Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively). In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.

Original languageEnglish
Pages (from-to)41143-41153
Number of pages11
JournalOncotarget
Volume8
Issue number25
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Ovarian Neoplasms
Neoplasm Metastasis
Brain
Androgen Receptors
Estrogen Receptors
Progesterone Receptors
Epidermal Growth Factor Receptor
Combined Modality Therapy
Neoplasms
Multivariate Analysis
Biomarkers
Immunohistochemistry
Ovarian epithelial cancer
Incidence

Keywords

  • Androgen receptor
  • Brain metastases
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Aandrogen receptor status predicts development of brain metastases in ovarian cancers. / Mittica, Gloria; Senetta, Rebecca; Scotto, Giulia; Aglietta, Massimo; Maggiorotto, Furio; Ghisoni, Eleonora; Genta, Sofia; Boldorini, Renzo; Manini, Claudia; Morra, Isabella; Buosi, Roberta; Sapino, Anna; Cassoni, Paola; Valabrega, Giorgio.

In: Oncotarget, Vol. 8, No. 25, 01.01.2017, p. 41143-41153.

Research output: Contribution to journalArticle

Mittica, G, Senetta, R, Scotto, G, Aglietta, M, Maggiorotto, F, Ghisoni, E, Genta, S, Boldorini, R, Manini, C, Morra, I, Buosi, R, Sapino, A, Cassoni, P & Valabrega, G 2017, 'Aandrogen receptor status predicts development of brain metastases in ovarian cancers', Oncotarget, vol. 8, no. 25, pp. 41143-41153. https://doi.org/10.18632/oncotarget.17068
Mittica, Gloria ; Senetta, Rebecca ; Scotto, Giulia ; Aglietta, Massimo ; Maggiorotto, Furio ; Ghisoni, Eleonora ; Genta, Sofia ; Boldorini, Renzo ; Manini, Claudia ; Morra, Isabella ; Buosi, Roberta ; Sapino, Anna ; Cassoni, Paola ; Valabrega, Giorgio. / Aandrogen receptor status predicts development of brain metastases in ovarian cancers. In: Oncotarget. 2017 ; Vol. 8, No. 25. pp. 41143-41153.
@article{4e34fffcc5804bc9a59e48c8895f72d8,
title = "Aandrogen receptor status predicts development of brain metastases in ovarian cancers",
abstract = "Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a {"}Control dataset{"} of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry forCases (both primary and metastatic lesions) and Controls. Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10{\%}, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively). In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.",
keywords = "Androgen receptor, Brain metastases, Ovarian cancer",
author = "Gloria Mittica and Rebecca Senetta and Giulia Scotto and Massimo Aglietta and Furio Maggiorotto and Eleonora Ghisoni and Sofia Genta and Renzo Boldorini and Claudia Manini and Isabella Morra and Roberta Buosi and Anna Sapino and Paola Cassoni and Giorgio Valabrega",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.17068",
language = "English",
volume = "8",
pages = "41143--41153",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "25",

}

TY - JOUR

T1 - Aandrogen receptor status predicts development of brain metastases in ovarian cancers

AU - Mittica, Gloria

AU - Senetta, Rebecca

AU - Scotto, Giulia

AU - Aglietta, Massimo

AU - Maggiorotto, Furio

AU - Ghisoni, Eleonora

AU - Genta, Sofia

AU - Boldorini, Renzo

AU - Manini, Claudia

AU - Morra, Isabella

AU - Buosi, Roberta

AU - Sapino, Anna

AU - Cassoni, Paola

AU - Valabrega, Giorgio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a "Control dataset" of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry forCases (both primary and metastatic lesions) and Controls. Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively). In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.

AB - Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a "Control dataset" of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry forCases (both primary and metastatic lesions) and Controls. Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively). In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.

KW - Androgen receptor

KW - Brain metastases

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85020908486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020908486&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17068

DO - 10.18632/oncotarget.17068

M3 - Article

AN - SCOPUS:85020908486

VL - 8

SP - 41143

EP - 41153

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -